Novo Nordisk renews ZymoGenetics deal for two years - San Francisco Business Times:

valvookimakaj1362.blogspot.com
The companies entered into a four-year optiom agreement in November 2000, when the spinoff Under the terms of the Novo Nordisk pays ZymoGenetics an annual feeof $7.5 In return, Novo Nordisk has the right to license exclusivwe rights to a limited number of proteinz outside North America. ZymoGenetics said all previous termxs of the agreement are stillin force, and the extension give s Novo Nordisk the option until November 2006. "Thr decision by Novo Nordisk to extend the optio n agreement is a vote of confidence in our abilitt to maintain the productivity of our proteindiscovery efforts," said Bruce L.A. Carter, president and chied executive officerof ZymoGenetics.
"Because we are focusedc on developing these proteinz for NorthAmerican markets, we are pleased to have a compant like Novo Nordisk committed to the development of proteins in the rest of the